Andere talen SCYNEXIS, Inc.

Aandelen

SCYX

US8112922005

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 15-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,26 ^USD	+14,72%		+22,83%	+1,35%

08/05	SCYNEXIS, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
09/04	SCYNEXIS, Inc. presenteert preklinische gegevens over de tweede generatie fungerp SCY-247 op het 34e Europese Congres voor Klinische Microbiologie en Infectieziekten	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M	08/05
Scynexis: Q1 Earnings Snapshot	08/05
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update	08/05
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)	30/04
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)	09/04
SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases	09/04
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update	28/03
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference	30/01
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference	29/01
SCYNEXIS, Inc. Presents Preclinical Data on Second Generation Fungerp SCY-247 Against Mucormycosis At the 11Th Advances Against Aspergillosis and Mucormycosis Conference	29/01
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	08/01
SCYX DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX	07/01
SCYX Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	07/01
Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX	06/01
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy	05/01
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit	04/01
SCYNEXIS Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options	04/01
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit	03/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen SCYNEXIS, Inc.

Aandelen

SCYX

US8112922005

Andere talen

Filters